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1. INTRODUCTION 
Oral route is the most convenient route of drug 
administration. Several marketed drugs and New Chemical 
Entities (NCEs) are poorly soluble in aqueous media 
leading to problems in absorption from the gastrointestinal 
tract after oral administration. Penetration of these kinds of 
compounds via intestinal mucosa can be enhanced using 
absorption enhancers, which can increase the 
bioavailability and efficacy of a drug candidate [1]. 
There are several permeability enhancers which can help 
compounds to permeate through the intestinal barriers. 
These enhancers are surfactants, fatty acids, medium chain 
glycerides, steroidal detergents, acyl carnitine and 
alkanoylcholines, N-acetylated α-amino acids and N-
acetylated non-α-amino acids, and chitosans and other 
mucoadhesive polyers [2]. Usage of permeability 
enhancers brings concerns of toxicity either in the GIT 
epithelium (in vivo) or disruption to the cell monolayer 
upon exposure (in vitro) [3]. This investigation aims to 
address and investigate the optimal levels of permeability 
enhancers which don’t cause any damage to the cell 
monolayer [4].  
To investigate the mechanisms involved in the 
bioavailability after oral administration Caco-2 monolayer 
model of epithelial cells have been widely used to study 
active and passive transport of drug molecules [5]. Caco-2 
cell line is derived from a human colorectal carcinoma and 
these cells strongly express P-gp transporter [6]. Because 
of their tumorous nature this cell system is widely used in 
in vitro screening technologies to predict gastrointestinal 
absorption and possible Pgp transport of NCE’s [7]. This 
model is also acceptable to FDA for in vitro evaluation of 
permeability for BCS Classification of drugs [8] and also 
for evaluating NCEs as a substrates and inhibitor of P-
glycoprotein (P-gp, MDR1).  
Caco-2 cells when cultured on semi permeable membranes 
differentiate into a highly functionalized epithelial barrier 
and forms tight junctions with remarkable morphological 
and biochemical similarity to the small intestinal columnar 
epithelium [9]. The membrane transport properties of 
novel compounds can thereby be assessed using this 
differentiated cell monolayer. The apparent permeability 
coefficients (Papp) obtained from Caco-2 cell transport 
studies have been shown to correlate to human intestinal 
absorption. 
This investigation will approach to summarize the optimal 
levels of absorption enhancer which do not cause any toxic 
effect on Caco-2 cell monolayer. 
2. MATERIALS AND METHODS 
2.1. Chemicals and apparatus 
Dulbecco’s Modified Eagles medium (DMEM) (Cat # 
D5671), trypsin-EDTA solution (Cat # T3924), Fetal 
Bovine Serum (FBS) (Cat # 12003C), Hanks Balanced salt 
solution HBSS (Cat # H6648), Lucifer yellow (L0529) and 
Loperamide (Cat # L4762) were purchased from Sigma, 
Germany. 3-(N, N-Dimethylpalmitylammonio) 
propanesulfonate (PPS), Cremphore EL and Peanut oil 
were purchased from Sigma, USA. T-75 flasks and 
serological pipettes were purchased from Grenier-Bio-one, 
Germany. Mill cell -24 well PET membrane 1µm plates 
(Cat # PSRP010 R5) were purchased from Millipore 
ABSTRACT 
The leading goal in new drug discovery is to have orally bioavailable drug. Poor permeability is one of the reasons for the 
poor bioavailability of several New Chemical Entities (NCEs). Permeability assessment using in vitro Caco-2 cell monolayer 
model is considered to be excellent model for screening of NCEs. Permeability enhancers can increase the permeability of 
compounds by paracellular or transcellular route. There are limitations to use the permeability enhancers due to concentration 
dependent toxic effect on cell monolayer, several times wrong interpretation can be made due to disrupted cell monolayer 
integrity. This study was performed on Caco-2 cell monolayer to identify optimal levels of commonly used permeability 
enhancers which does not cause any damage to the cell monolayer. The assessment involved pre and post TEER measurement 
and leak test using Lucifer yellow (LY) rejection assay. Total 16 permeability enhancers were tested and optimum levels were 
as per parenthesis: peanut oil (10%), Cremphore EL,  Miglyol 812, Oleic acid, Propylene glycol (1%), Capmul MCM C8 EP, 
glycerol, Labrasol, MC8-2, PEG 400, Polysorbate 80, Sporiol TPGS, Transcutol (0.1% ), Capmul , Solutol (0.01% ) and for 
PPS (0 .0001%). It was important to determine the optimal levels of each permeability enhancer to avoid any false positive 
results.  
Keywords: Permeability enhancers, Caco-2 cell line, TEER, % LY rejection, Tight Junctions 
 
Rastogi et al                                Journal of Drug Delivery & Therapeutics; 2013, 3(3), 20-29   21 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
 
 
Corporation, Billerica MA. Labrasol and Transcutol were 
purchased from Gattefosse, Saint Priest cedex, France. 
Oleic aicid, Solutol HS 15 and PEG-400 were purchased 
from BASF, Germany.  Glycerol and Propylene glycol 
were purchased from Merck, USA. Polysorbet 80 was 
purchased from Croda, Europe. Capmul, MC8-2 and 
Capmul MCM C8 EP were purchased from ABITEC, 
Jackson st. Janesvile. Sporiol TPGS was purchased from 
Cognis Pharma. Miglyol 812 was purchased from sasol, 
Germany    
CO2 incubator (Thermo Scientific, 81 Wyman Street, 
Waltham, MA), Millicell ERS voltommeter (Millipore 
Corporation, Billerica MA), Centrifuge (Kubota, Tokyo, 
Japan), LC-MS/MS (Shimadzu Prominence LC-20AD, 
SIL-HTc, CTO-20AC, Japan; API-4000 MDS Sciex, 
Applied Biosystems, Canada), Micro plate Shaker (VWR) 
and Infinite F 200 PRO Multimode Reader (Tecan, 
Austria). 
2.2. Cell culture 
Caco-2 cells were procured from National Center for Cell 
Sciences (NCCS), Pune, India. The Caco-2 cells were 
cultured in DMEM supplemented with 10% FBS and 2% 
penicillin–streptomycin in a 37◦C with 5% CO2 humidified 
incubator. The cells were harvested at approximately 80–
90% confluency using 0.25% trypsin–EDTA 
(Ethylenediaminetetraacetic acid). The cells (passage 
number # 36) were then seeded onto transwell inserts at a 
density of 0.8 x 105 cells/cm2 and grown for 21 days. 
Medium was changed every alternative days and 100% 
confluent monolayer of cells on the inserts was used for 
transport assays. The formation of confluent monolayers 
and tight junctions was tested and confirmed by measuring 
transepithelial electrical resistance (TEER) across the cell 
monolayers from day 15 onwards. 
2.3. Dosing solutions preparations of permeability 
enhancer  
Different percentages of permeability enhancers are 
prepared as described below and shown in table 1. 
 Capmul was weighed and liquefied at 45ºC in water 
bath for 10 min to prepare 10% stock in HBSS (Hanks 
Balanced salt solution). These were further diluted to 
1%, 0.1% and 0.01% using HBSS. 
 Cremophore EL, glycerol, Labrasol, MC8-2, Miglyol 
812, Oleic acid, Peanut oil, PEG 400, Polysorbet 80, 
Propylene glycol and transcutol was added to HBSS 
buffer to prepare 10% stock, which were further 
diluted to 1% and 0.1% using HBSS. 
 PPS was weighed and stock of 1% is prepared in 
HBSS. These were further diluted to 0.01%, 0.001% 
and 0.0001% using HBSS. 
 Spiriol TPGS, Solutol and Capmul MCM C8 was 
weighed and liquefied at 45ºC in water bath for 10 
min to prepare 10% stock in HBSS. These were 
further diluted to 1% and 0.1% using HBSS. 
2.4. Measurement of TEER 
The TEER test was performed using a Millicell ERS 
voltommeter, following equation was used to calculate the 
TEER values (Ω cm2) across the cell monolayers: 
TEER = (R − Rblank) A 
Where, R is the measured resistance across a cell 
monolayer, Rblank is the resistance of a blank well and A is 
the surface area of the transwell filter (0.7cm2). TEER 
values were measured and wells showing TEER values 
above 230 Ω cm2 were taken for experiments, indication of 
formation of a cell monolayer with tight junctions. TEER 
values were also measured at the end of assay (120 min) to 
assess the toxic effects of permeability enhancers on the 
cell membrane’s integrity. 
Table 1: Summary table for different percentages of 
permeability enhancers used for assay 
Permeability enhancer Percentage used for assay 
Capmul 10, 1, 0.1 and 0.01% 
Capmul MCM C8 EP 10, 1 and  0.1 % 
CremphoreEL 10, 1 and  0.1% 
Glycerol 10, 1 and  0.1% 
Labrasol 10, 1 and  0.1% 
MC8-2 10, 1 and  0.1% 
Miglyol 812 10, 1 and  0.1% 
Oleic Acid 10, 1 and  0.1% 
PEG 400 10, 1 and  0.1% 
Peanut Oil 10, 1 and  0.1% 
Polysorbate 80 10, 1 and  0.1% 
PPS 0.01, 0.001 and 0.0001% 
Propylene Glycol 10, 1 and  0.1% 
Solutol 10, 1, 0.1 and 0.01% 
Sporiol TPGS 10, 1 and  0.1% 
Transcutol 10, 1 and  0.1% 
 
2.5. Lucifer Yellow (LY) Rejection Assay 
Lucifer yellow travel across cell monolayer only through 
paracellular diffusion and has low permeability. As a result 
it’s not possible to cross cell monolayer when tight 
junctions are well maintained. The integrity of the 
monolayer was measured by monitoring the lucifer yellow 
rejection, a paracellular marker across cell monolayer.  
LY fluorescence (RFU) was measured at 485/535nm and 
the percent rejection of LY was calculated using formula: 
       % LY Rejection = 100 [1- RFU basolateral / RFU apical] 
Where, RFU is relative fluorescence units. After the 
completion of last time point sampling (120 min), 100 µL 
samples from apical and basal compartment was measured 
for lucifer yellow RFU. The % LY rejection values > 99% 
suggests the integrity of monolayer was maintained within 
duration of experiment. 
2.6. Transport studies 
Transport studies across the monolayer of Caco-2 cells 
were performed by washing the cell monolayer twice with 
HBSS and incubated for 40 min in CO2 incubator. TEER 
values were measured and wells showing TEER values 
above 230 Ω cm2 were taken for experiments.  
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Dosing solutions for different percentage of permeability 
enhancers prepared in HBSS were added on apical side of 
monolayer (A→B transport) followed by adding 800 µL of 
HBSS on basal side. After completion of experiment (120 
min) samples were collected from apical and basal 
compartment for Lucifer Yellow Rejection followed by 
post experiment TEER values. 
To assess the functionality of P-glycoprotein (P-gp) on 
Caco-2 cell monolayer loperamide was run as a positive 
control at 5µM concentration (A→B / B→A; pH 7.4 / 7.4), 
study will be initiated by adding 400 µL of loperamide 
prepared in HBSS in apical (A→B transport) followed by 
addition of 800 µL of HBSS on basal side and for B→A 
transport 800 µL of loperamide prepared in HBSS will be 
dosed in basal followed by addition of 400 µL HBSS on 
apical side. At selected time points (0, 30, 60 and 120 
minutes) an aliquot of 50 µL will be collected from the 
receiver compartment for determination of test compound 
concentrations. The volume withdrawn will be replaced 
immediately with HBSS buffer. 50 µL aliquot of test 
samples collected at respective time points were diluted 
with acetonitrile containing suitable internal standard were 
vortexed for 5 minutes and 100 µL will be transferred to 
insert vials and analyzed using LC-MS/MS.  Lucifer 
Yellow Rejection and TEER will be measured at the end to 
the experiment to confirm any damage of monolayer while 
performing experiment.  
2.7. Data Analysis 
The apparent permeability (Papp) (A→B and B→A) of test 
compounds and positive control will be calculated using 
the following formula: 
Papp = dQ/dt / A.Co 
Where, dQ/dt – linear slope of test compound 
concentration in receptor chamber with time (0, 30, 60 and 
120 min) after correcting for dilution.  
A – Area of the filter (0.7 cm2); Co – Initial concentration 
of compound in the donor compartment. 
Efflux ratio (RE) will be calculated using the following 
equation: 
RE = PB/A / PA/B 
Where PB/A and PA/B represent the apparent permeability of 
test compound from the basal to apical and apical to basal 
side of cell monolayer. The compounds having efflux ratio 
of > 2 is considered as having potential for P-gp substrate. 
3. RESULTS  
3.1. Bi-directional transport of loperamide in Caco-2 
cells 
Bi-directional transport of loperamide was performed to 
assess the functionality of P-glycoprotein (P-gp) on Caco-2 
cell monolayer.  Apparent permeability coefficients (Papp) 
of Loperamide were calculated to assess the functionality 
of P-glycoprotein (P-gp) on Caco-2 cell monolayer is 5.04 
x 10-6 cm/sec for A→B transport and 16.6 x 10-6 cm/sec 
for B→A transport. Papp values for bi-directional 
transport of loperamide are shown in Table1. Loperamide 
showed an efflux ratio of 3.3 confirming that P-gp is active 
in cell monolayer evident from Table 2 and Fig.1. The 
efflux ratio obtained with loperamide transport is within 
range as reported 10. 
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Figure 1: Bi-directional transport of loperamide across 
Caco-2 cells in absence and presence of P-gp inhibitor 
verapamil. The apparent A→B and B→A permeability 
(Papp; 10-6 cm/sec) of loperamide (5µM) showed an 
efflux ratio of 3.3 which dropped down to 0.9 in presence 
of P-gp inhibitor verapamil (100µM) 
Table 2: Table representing Papp and efflux ratios of loperamide 
Compounds No. of replicates Concentration (µM) 
Papp  
(10
-6
 cm/sec) 
Efflux ratio (RE) 
Loperamide (A→B) 3 
5 
5.04 ± 0.79 
3.3 
Loperamide (B→A) 3 16.6 ± 0.4 
Loperamide+ Verapamil (A→B) 3 
5 
14.6 ± 1.7 
0.9 
Loperamide+ Verapamil (B→A) 3 13.7 ± 0.3 
 
3.2. Inhibition studies of loperamide with verapamil 
across Caco-2 cells 
Addition of verapamil (100µM) to both compartments 
diminishes the P-gp mediated efflux. Inhibitory effect 
produced is observed through a decrease in loperamide 
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B→A transport and an increase in A→B transport. 
Verapamil (100µM) significantly inhibited the loperamide 
B→A transport and improved A→B transport. The change 
in Papp values is depicted in Table 2 and Fig. 1. A→B and 
B→A Papp values for loperamide transport after addition 
of verapamil was found to be 14.6 x 10-6 cm/sec and 13.7 x 
10-6 cm/sec, respectively. After addition of P-gp inhibitor 
loperamide showed an efflux value of 0.9 confirming that 
P-gp is active in cell monolayer. 
3.3. TEER measurements 
TEER measurements were made both prior to and at the 
end of experiment as drop in TEERs indicating the 
opening of tight junctions which might be due to toxicity 
caused by usage of various percentages of permeability 
enhancers, as evident in Fig. 2-17. 
3.4. % LY rejection values 
Monolayer integrity was tested by Lucifer yellow (LY) 
rejection, percent rejection of LY was calculated and the 
various percentages of permeability enhancers showing 
values < 99% are considered to have toxic effect on Caco-
2 cell monolayer, as evident in Fig. 2-17. 
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Figure 2 - Pre and Post TEER along with % Lucifer yellow (LY) rejection for Capmul. Four different percentages 10, 1, 
0.1 and 0.01% of Capmul were used on Caco-2 cell monolayer and no toxic effect was observed at 0.01%  
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Figure 3 - Pre and Post TEER along with % Lucifer yellow (LY) rejection for Capmul MCM E8. Three different 
percentages 10, 1 and 0.1 % of Capmul MCM E8 were used on Caco-2 cell monolayer and no toxic effect was observed at 
0.1% 
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Figure 4: Pre and Post TEER along with % Lucifer yellow (LY) rejection for Cremphore EL. Three different percentages 
10, 1 and 0.1 % of Cremphore EL were used on Caco-2 cell monolayer and no toxic effect was observed at 1% 
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Figure 5 - Pre and Post TEER along with % Lucifer yellow (LY) rejection for Glycerol. Three different percentages 10, 1 
and 0.1 % of Glycerol were used on Caco-2 cell monolayer and no toxic effect was observed at 0.1% 
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Figure 6 - Pre and Post TEER along with % Lucifer yellow (LY) rejection for Labrasol. Three different percentages 10, 1 
and 0.1 % of Labrasol were used on Caco-2 cell monolayer and no toxic effect was observed at 0.1% 
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Figure 7 - Pre and Post TEER along with % Lucifer yellow (LY) rejection for MC8-2. Three different percentages 10, 1 
and 0.1 % of MC8-2 were used on Caco-2 cell monolayer and no toxic effect was observed at 0.1% 
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Figure 8 - Pre and Post TEER along with % Lucifer yellow (LY) rejection for Miglyol 812. Three different percentages 
10, 1 and 0.1 % of Miglyol 812 were used on Caco-2 cell monolayer and no toxic effect was observed at 1% 
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Figure 9: Pre and Post TEER along with % Lucifer yellow (LY) rejection for Oleic acid. Three different percentages 10, 1 
and 0.1 % of Oleic acid were used on Caco-2 cell monolayer and no toxic effect was observed at 1% 
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Figure 10: Pre and Post TEER along with % Lucifer yellow (LY) rejection for Peanut oil. Three different percentages 10, 
1 and 0.1 % of Peanut oil were used on Caco-2 cell monolayer and no toxic effect was observed at 10% 
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Figure 11: Pre and Post TEER along with % Lucifer yellow (LY) rejection for PEG 400. Three different percentages 10, 1 
and 0.1 % of PEG 400 were used on Caco-2 cell monolayer and no toxic effect was observed at 0.1% 
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Figure 12: Pre and Post TEER along with % Lucifer yellow (LY) rejection for Polysorbate 80. Three different percentages 
10, 1 and 0.1 % of Polysorbate 80 were used on Caco-2 cell monolayer and no toxic effect was observed at 0.1% 
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Figure 13: Pre and Post TEER along with % Lucifer yellow (LY) rejection for PPS. Three different percentages 0.01, 
0.001 and 0.0001% of PPS were used on Caco-2 cell monolayer and no toxic effect was observed at 0.0001% 
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Figure 14: Pre and Post TEER along with % Lucifer yellow (LY) rejection for Propylene Glycol. Three different percentages 10, 
1 and 0.1 % of Propylene Glycol were used on Caco-2 cell monolayer and no toxic effect was observed at 1% 
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Figure 15: Pre and Post TEER along with % Lucifer yellow (LY) rejection for Solutol. Four different percentages 10, 1, 
0.1 and 0.01% of Solutol were used on Caco-2 cell monolayer and no toxic effect was observed at 0.01% 
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Figure 16 - Pre and Post TEER along with % Lucifer yellow (LY) rejection for Sporiol TPGS. Three different percentages 
10, 1 and 0.1 % of Sporiol TPGS were used on Caco-2 cell monolayer and no toxic effect was observed at 0.1% 
Tr
an
sc
ut
ol
 (1
0%
)
Tr
an
sc
ut
ol
 (1
%
)
Tr
an
sc
ut
ol
 ( 
0.
1 
%
)
0
200
400
600
90
93
95
95
98
100
Pre TEER Post TEER % LYR
T
E
E
R
 (
o
h
m
 c
m
2
)
%
 L
u
c
ife
r y
e
llo
w
 (L
Y
) re
je
c
tio
n
 
Figure 17 - Pre and Post TEER along with % Lucifer yellow (LY) rejection for Transcutol. Three different percentages 10, 
1 and 0.1 % of Transcutol were used on Caco-2 cell monolayer and no toxic effect was observed at 0.1% 
  
4. DISCUSSION 
Compiling the data generated by  pre and post TEER 
measurement and leak test using Lucifer yellow (LY)  
rejection assay as evident in Fig. 18, the  ideal levels of 
permeability enhancer which is not toxic to cell monolayer 
are as per parenthesis: peanut oil (10%), Cremphore EL,  
Miglyol 812, Oleic acid, Propylene glycol (1%), Capmul 
MCM C8 EP, glycerol, Labrasol, MC8-2, PEG 400, 
Polysorbate 80, Sporiol TPGS, Transcutol (0.1% ), 
Capmul , Solutol (0.01% ) and for PPS (0 .0001%).
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Figure 18 - Ideal percentage of permeability enhancers on Caco-2 monolayer 
5. CONCLUSION 
This article addresses the optimum levels of commonly 
used permeability enhancers in Caco-2 cell lines to predict 
the oral bioavailability These enhancers generally 
increases the intestinal membrane permeability which is 
similar to Caco-2 cell monolayer permeability. The critical 
issue considered in evaluating this approach is the toxic 
effect and damage of cell monolayer by the usage of 
permeability enhancers. The categories of permeation 
enhancers discussed are surfactants, fatty acids, medium 
chain glycerides, steroidal detergents, acyl carnitine and 
alkanoylcholines, N-acetylated α-amino acids and N-
acetylated non-α-amino acids, and chitosans and other 
mucoadhesive polyers. This can be a potential approach in 
selecting appropriate enhancer to improve oral 
bioavailability of poorly absorbed compounds. This will 
reduce the attrition during in vivo assessment of oral 
bioavailability improvement.     
ACKNOWLEDGEMENTS 
Authors are thankful to Sai Life Sciences Ltd for providing 
all the necessary facility support to carry out the work 
successfully and the members of the Sai Life Sciences Ltd 
who have helped directly and indirectly to the work 
discussed in this manuscript. 
Conflict of Interest Statement 
The authors confirm that there are no conflicts of interest.
 
REFERENCES 
1. Aungst BJ, Intestinal permeation enhancers. J Pharm Sci. 2000, 
89, 429-42. 
2. Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, and 
Ambudkar SV, Comparison of drug transporter levels in normal 
colon, colon cancer, and Caco-2 cells: impact on drug disposition 
and discovery, Mol Pharm 2006, 3,87–93. 
3. http://www.fda.gov/cder/drug/drugInteractions/default.htm 
Guidance for Industry: Drug Interaction Studies —Study Design, 
Data Analysis and implications for Dosing and Labeling. FDA 
September 2006 Clinical Pharmacology. 
4.  http://www.fda.gov/cder/guidance/index.htm Guidance for 
Industry: Waiver of In Vivo Bioavailability and Bioequivalence 
Studies for Immediate-Release Solid Oral Dosage Forms Based on 
a Biopharmaceutics Classification System. FDA August 2000 BP.  
5. Hidalgo IJ, Raub TJ, and Borchardt RT, Characterization of the 
human colon carcinoma cell line (Caco-2) as a model system for 
intestinal epithelial permeability, Gastroenterology 1989, 96, 736-
749.  
6. Michael H., Eric H., Sang P. and Peng A., Effect of permeability 
enhancers for polar drug transport across Caco-2 cell monolayers. 
AAPS annual meeting 2008; Atlanta, GA. 
7. Remington: The Science and Practice of Pharmacy, Extended-
Release and targeted drug delivery system. Xuan Ding, Adam WG 
Alani, Joseph R Robinson. Lippincott Williams & Wilkins, USA; 
2006. P. 939-964.  
8. Romsicki, Y., Sharom, F.J., The membrane lipid environment 
modulates drug interactions with the P-glylcoprotein multidrug 
transporter. Biochemistry 1999, 38, 6887-6896.  
9. Smart JD, The basics and underlying mechanisms of 
mucoadhesion. Adv. Drug Del. Rev. 57 2005, 1556-1568. 
10. Stoner, C.L., Whittico, M.T., Fountain, S.T., Buchholz, L.M., 
Surendran, N., Chan, O.H., Stewart, B.H., Oh, D.M., High 
throughput P-glycoprotein interaction screening in Caco-2 cells for 
drug discovery compounds. AAPS Annual conference 2000; 
Indianapolis.
 
 
 
 
